Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Korsana Biosciences, Inc. Common Stock

KRSA

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.

Last trade $32.36
Day change -$0.32 (-0.98%)
Day range $30.69 – $33.15
Volume 134,991
Market cap $1.49B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for KRSA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for KRSA.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Tenet Healthcare is projected to report Q3 2026 earnings of $4.60 per share (up 24.3% YoY) on revenues of $5.47 billion (up 3.5% YoY). The company's Ambulatory Care segment is expected to drive growth with 8.4% revenue increase and 9.3% adjusted EBITDA growth. However, hospital patient days may decline 3.7% with increased utilization costs partially offsetting gains. The stock has an Earnings ESP of +11.11% and Zacks Rank #3, suggesting a likely earnings beat.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.